Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications through RFA-AI-27-018 to support large-scale implementation research aimed at improving the uptake, sustainment, and spread of evidence-based HIV prevention, treatment, and care interventions within significantly impacted U.S. communities. This funding opportunity utilizes a phased R61/R33 award structure, where the initial R61 phase focuses on study start-up and planning for up to two years with direct costs limited to 750,000 dollars per year. Successful completion of defined milestones in the first phase allows for a transition to the R33 implementation phase, which can last up to four years with no specific budget limit, provided the total project duration does not exceed five years. Eligible applicants include for-profit organizations, institutions of higher education, nonprofits, and various government entities, though foreign entities and foreign subawards are strictly prohibited. Proposals must be grounded in implementation science, utilize Hybrid Type II or III designs or full implementation trials, and demonstrate meaningful community engagement and preliminary data. Awards are determined by an overall impact score based on significance, innovation, approach, investigator expertise, and environment. Total funding is distributed across multiple NIH institutes, including NIMH, NHLBI, and NICHD, with a combined allocation exceeding 26 million dollars. Applicants must maintain active SAM and eRA Commons registrations and adhere to strict cybersecurity incident reporting and clinical trial registration requirements.